Navigation Links
Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
Date:4/30/2013

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals Inc., announced that the United States Patent and Trademark Office has issued patents that cover CAT-1000 and CAT-2000 series compounds. One patent (U.S. Patent No. 8,173,831) covers the CAT-1000 series' conjugation of salicylate and an omega-3 fatty acid using Catabasis' SMART Linker technology; the compounds in this series are intended to treat diseases involving chronic inflammation such as inflammatory bowel disease and Duchenne muscular dystrophy. CAT-2000 series' patents (U.S. Patent Nos. 8,304,551 and 8,304,552) cover SMART Linker conjugation of niacin and an omega-3 fatty acid. CAT-2003, the series' lead compound, is being tested for patients with severe hypertriglyceridemia. The patents cover composition of matter for both series, including lead products CAT-1004 and CAT-2003, until 2029 and 2030 respectively.

"These patents, along with others in our portfolio, provide multi-layered protection for our SMART Linker conjugates in the CAT-1000 and CAT-2000 series," said Jill Milne , Ph.D., chief executive officer of Catabasis. "The patents validate our unique chemistry platform. We create new compounds, conjugated using our SMART Linker technology, giving us the ability to
'/>"/>

SOURCE Catabasis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
8. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
9. Cumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
10. Horizon Technology Finance Closes $2 Million Venture Loan Facility with New Haven Pharmaceuticals
11. Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NEW YORK , Nov. 25, 2014 /PRNewswire/ ... with Covidien has been widely discussed in ... but it,s also creating a stronger leading player ... according to Kalorama Information.  The healthcare market research ... monitoring systems will feature a diverse set of ...
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... of choice for certain newly diagnosed patients with chronic myeloid leukemia , ... of cancer cells in 96% of Tasigna patients and reduction of abnormal ... Larger front-line Phase III trial evaluating Tasigna vs. Gleevec(R) now fully accrued ... , EAST HANOVER, N.J., Dec. 8 ...
... SAN FRANCISCO, Dec. 8 Millennium: The ... two large, multi-center,randomized Phase III clinical trials ... of transplant-eligible patients with previously untreated,multiple myeloma ... one study comparing VELCADE and dexamethasone (VcD) ...
Cached Medicine Technology:Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 2Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 3Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 4Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 5Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 6Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 7Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 8Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 9Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 10Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 11Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 12Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 13Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 2Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 3Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 5Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 7
(Date:11/27/2014)... Developers and plugin specialist of Final Cut Pro ... FCPX to the next level. , “ProPip allows users to ... of a mouse,” said Christina Austin, CEO of Pixel Film ... appreciate.” , With ProPip users can show off their ... ProPip is great for commentaries, news casting, and more. PROPIP™ ...
(Date:11/27/2014)... 2014 Aria Health President and ... prepared and donated 200 Thanksgiving dinners on Friday, ... , a non-profit, community-based organization committed to serving ... The dinners were assembled in the dining hall ... distributed to vulnerable low income seniors in the ...
(Date:11/27/2014)... New Delhi, India (PRWEB) November 27, 2014 ... firm, has announced a search engine optimization service ... that small businesses or start-ups cannot afford costly ... introduced this service package, keeping their affordablity and ... reduced the service cost, but it has not ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 VeloReality Inc. ... six new Real Life Videos (RLVs) of world-famous velo courses ... Trainer, as well as other popular indoor velo trainers. Two ... available worldwide before the end of November -- in ... the total number of rides in the VeloReality collection to ...
(Date:11/26/2014)... Il (PRWEB) November 27, 2014 ... excited to announce the kick-off of its annual ... encourages people to go to donate to those ... partner with local organizations to distribute the donations ... 20th, participating AlignLife locations will be accepting donations ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3
... -- The growing number of people with Alzheimer,s disease in ... a responsibility that health experts warn can pose risks to ... to protect their health, says Rebecca Axline, a clinical social ... To keep stress in check, for instance, she emphasizes the ...
... HealthDay Reporter , WEDNESDAY, April 27 (HealthDay News) -- ... sugar control, often sending people with type 2 diabetes ... that happens. Now, a new study provides some ... decline dramatically in those who have the bypass surgery, ...
... brainy bookworms unprepared for the rough and tumble of post-graduation ... tend to fade away quickly when injected into cancer patients. ... can cause such cells to survive in patients, bloodstreams for ... of other, highly toxic treatments, a new study shows. ...
... Researchers in New York City say they are the first ... cells. A team at Albert Einstein College of Medicine ... gene transcription in living yeast cells, they say. Transcription occurs ... messenger RNA (mRNA) that then make the protein coded by ...
... , WEDNESDAY, April 27 (HealthDay News) -- An ... than earlier medications will be reviewed Thursday by a panel ... Telaprevir, made by Vertex Pharmaceuticals of Cambridge, Mass., would be ... levels of the virus, which can cause severe liver damage, ...
... (ASTRO) has developed a guideline for the use of ... to palliate thoracic symptoms caused by advanced lung cancer. ... Oncology , an official journal of ASTRO. Many patients ... treat symptoms related to cancer, such as cough, shortness ...
Cached Medicine News:Health News:Alzheimer's Caregivers Need Care, Too 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 2Health News:New Clues to How Gastric Bypass Surgery Combats Diabetes 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 2Health News:New technique extends cancer-fighting cells' potency in melanoma patients 3Health News:New technique extends cancer-fighting cells' potency in melanoma patients 4Health News:Researchers Describe Gene Activity in Living Cells 2Health News:Novel Hepatitis C Drug Holds Promise: FDA 2Health News:ASTRO publishes evidence-based guideline for thoracic radiotherapy 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: